Euro
USD
British Pound
NULL
Product Description
FLT3 (phospho Tyr842) Antibody | 79-845 | ProSci
Host: Rabbit
Reactivity: Human, Mouse
Homology: N/A
Immunogen: FLT3 (phospho Tyr842) antibody was raised against a peptide sequence around phosphorylation site of tyrosine 842 (S-N-Y (p) -V-V) derived from Human FLT3 .
Research Area: Phospho-Specific
Tested Application: WB
Application: Western Blot: 1:500~1:1000
Specificiy: The antibody detects endogenous levels of FLT3 only when phosphorylated at tyrosine 842.
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 170 kDa
Validation: N/A
Isoform: N/A
Purification: Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+) , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration: 1 mg/mL
Storage Condition: Store antibody at -20˚C for up to one year.
Alternate Name: CD135, STK1, FLK-2, FLT-3
User Note: N/A
BACKGROUND: FLT3 encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
